ESTRO 2024 - Abstract Book

S4728

Physics - Optimisation, algorithms and applications for ion beam treatment planning

ESTR0 2024

References:

[1] Habl G, Uhl M, Katayama S, et al. Acute Toxicity and Quality of Life in Patients with Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study - The IPI Trial. IJROBP. 2016;95(3):435-433. doi:10./1016/j.ijrobp.2016.02.025

[2] Ishikawa H, Tsuji H, Kamada T, et al. Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. Radiother Oncol. 2006;81(1):57-64. doi:10.1016/j.radonc.2006.08.015

3190

Proffered Paper

Can spot-scanning hadron arc be used as stereotactic radiosurgery of multiple brain metastases?

Lennart Volz 1 , Peilin Liu 2 , Thomas Tessonnier 3 , Marco Durante 1,4 , Andrea Mairani 3 , Christian Graeff 1,5 , Taoran Li 6,3

1 GSI Helmholtz Center for Heavy Ion Research GmbH, Biophysics, Darmstadt, Germany. 2 Beaumont Health, Department of Radiation Oncology, Royal Oak, USA. 3 University Hospital Heidelberg, Heidelberg Ion Beam Therapy Center, Heidelberg, Germany. 4 Technical University of Darmstadt, Insitute of Condensed Matter Physics, Darmstadt, Germany. 5 Technical University of Darmstadt, Department of Electrical Engineering and Information Technology, Darmstadt, Germany. 6 Univeristy of Pennsylvania, Department of Radiation Oncology, Perelman School of Medicine, Philadelphia, USA

Purpose/Objective:

Multiple metastases (multi-met) in the brain are the most common type of brain lesions. The state-of-the-art radiation treatment is single-isocenter stereotactic radiosurgery (SISRS), facilitating sharp dose gradients and maximizing the sparing of the healthy brain [1]. Despite technological advances, however, treatment of brain multi-mets remains a challenge with poor prognosis. Fully exploiting the superior dose profile of ion beams, recent works have indicated enormous potential of spot-scanning proton (SPArc) and hadron arcs (SHArc) for improving dose conformity for various diseases, including for single metastases[2]. Leveraging these advances, we developed bespoke treatment planning infrastructure for SPArc and SHArc multi-met SISRS and evaluated this novel treatment opportunity on a cohort of patients exhibiting three to twelve brain metastases.

Material/Methods:

Through a collaboration established at the ESTRO particle arc workshop 2023, existing SPArc and SHArc algorithms implemented in research (TriP98, FROG) and clinical (RayStation, Raysearch Laboratories, Sweden) treatment planning systems were extensively extended to permit simultaneous dose optimization for multiple targets. The implemented frameworks facilitate both iterative and heuristic energy selection procedures, selection of sub-arcs, as well as non-coplanar SPArc and SHArc trajectories. Through rigorous memory and run-time efficiency optimization, fast robust biological dose optimization for SHArc( 12 C) was made possible in the TriP98 treatment planning platform,